


TMH:dv 6/24/05 4239-66904-02

E-293-2002/0-US-03

PATENT

Attorney Reference Number 4239-66904-02



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: *Cuttitta et al.*

Application No. 10/529,118

Filed: March 24, 2005

Confirmation No. \_\_\_\_\_

For: VASOREGULATING COMPOUNDS AND  
METHODS OF THEIR USE

Examiner: \_\_\_\_\_

Art Unit: \_\_\_\_\_

Attorney Reference No. 4239-66904-02

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed June 27, 2005

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Supplemental Information Disclosure Statement  
☒ Form 1449 and 4 references cited thereon

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed. Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.  
Registration No. 42,630

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Docketing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: *Cuttitta et al.*

Application No. 10/529,118

Filed: March 24, 2005

Confirmation No. \_\_\_\_\_

For: VASOREGULATING COMPOUNDS AND  
METHODS OF THEIR USE

Examiner: \_\_\_\_\_

Art Unit: \_\_\_\_\_

Attorney Reference No. 4239-66904-02

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s) \_\_\_\_\_

Tanya M. Harding, R.D.

Date Mailed June 27, 2005

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are four English-language and/or non-English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.


Applicants are filing this Information Disclosure Statement ("IDS") before the mailing of a first Office action on the merits. It is believed that no fee is due to file this IDS. If the Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP


By



Tanya M. Harding, Ph.D.  
Registration No. 42,630

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Docketing

 <p align="center"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p>	Attorney Docket Number	4239-66904-02
	Application Number	10/529,118
	Filing Date	March 24, 2005
	First Named Inventor	Cuttitta
	Art Unit	
	Examiner Name	

### U.S. PATENT DOCUMENTS

Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,831,004	November 3, 1998	Campbell <i>et al.</i>
		6,117,869	September 12, 2000	Picard <i>et al.</i>
		6,133,304	October 17, 2000	Peterson, Jr., <i>et al.</i>
		6,265,432	July 24, 2001	Purchase, Jr. <i>et al.</i>
		6,307,101	October 23, 2001	Campbell <i>et al.</i>
		6,339,160	January 15, 2002	Politi <i>et al.</i>
		6,350,885	February 26, 2002	O'Brien <i>et al.</i>

### FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

### OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Corcoran <i>et al.</i> , "MMP-2: Expression, Activation and Inhibition," <i>Enzyme Protein</i> 49:7-19 (1996)
		Giannelli and Antonaci, "Gelatinases and their inhibitors in tumor metastasis: form biological research to medical applications," <i>Histol Histopathol</i> 17:339-345 (2002)
		Kleiner and Stetler-Stevenson, "Matrix metalloproteinases and metastasis," <i>Cancer Chemother Pharmacol</i> 43(Suppl):S42-S51 (1999)
		Kugler <i>et al.</i> , "Matrix Metalloproteinases and their Inhibitors," <i>Anticancer Research</i> 19:1589-1592 (1999)

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	